VANCOUVER, June 28 /PRNewswire-FirstCall/ - Chemokine Therapeutics Corp. (the “Company”) , a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, announced today that Guy Ely, M.D. has been appointed to serve as Chief Medical Officer, and will be responsible for overseeing Chemokine’s overall clinical development program and regulatory filings.
Dr. Ely brings Chemokine over 21 years international experience in the pharmaceutical industry with proven expertise in medical affairs and clinical research/development of drugs in the fields of oncology, cardiovascular, anti- infectives and rheumatology. During his impressive career, Dr. Ely has supervised over 150 clinical trials. His strong business orientation with emphasis in strategic planning, business development and product evaluation have served to earn Dr. Ely international regard as a proven senior executive physician and professional consultant in the global biotech arena.
Prior to joining Chemokine, Dr. Ely served as Vice President, Clinical and Medical Affairs at Biomira, Inc., where he supervised the global clinical development of the Company’s lead cancer vaccines. As Vice President, Clinical and Medical Affairs at Lorus Therapeutics, Dr. Ely directed the global clinical development of anti-cancer drugs, including leading the Phase III planning of the lead immunotherapeutic compound for pancreatic cancer in Canada and the United States. While serving as Associate Medical Director at SmithKline Beecham Canada, Inc. (now, Glaxo Beecham), he directed all clinical research and development activities, including execution of approximately 50 international clinical trials in Canada. Prior senior posts also included Vice President, Clinical and Medical Affairs at Biochem Therapeutics, Inc.; Director, Clinical Research at Abbott Laboratories Canada Inc.; Medical Director at Asta Medica, France; Manager of Clinical Investigation and Medical Advisor for Ciba-Geigy Canada, Inc.; Medical Director of A.C.I.C. Ltd; and Professor of Biology and Physics at French Lycee of New York. Dr. Ely earned his Doctorate of Medicine degree from the University Paris XII: C.H.U. Henri Mondor with Certificates in Stomatology and Biochemistry.
“In Dr. Ely, we believe we have found the ideal combination of industry experience, knowledge and relationships, and fully anticipate that he will be a driving force behind the ongoing success of our clinical research and development efforts,” stated Dr. Hassan Salari, President and CEO of Chemokine Therapeutics Corp.
About Chemokine Therapeutics Corp.
Chemokine Therapeutics is a product-focused biotechnology company developing drugs in the field of chemokines. Chemokines are a class of signaling proteins which play a critical role in the growth, differentiation and maturation of cells necessary for fighting infection, and stem cells, as well as tissue repair and regeneration. Chemokine Therapeutics is a leader in research in the field of chemokines and has several products in various stages of development. For more information, please visit the Company’s website at www.chemokine.net.
Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: Statements in this document regarding management’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “projects”, and similar expressions are intended to identify forward-looking statements. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances, or events to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, those associated with the success of research and development programs, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company’s products, the availability of government and insurance reimbursements for the Company’s products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and other risks detailed from time-to-time in the Company’s public disclosure documents and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward- looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
For further information contact: Elite Financial Communications Group Chemokine Investor Relations Dodi Handy President & CEO Phone: 407.585.1080 E-mail: chkt@efcg.net
Chemokine Therapeutics Corp.
CONTACT: Elite Financial Communications Group, Chemokine InvestorRelations, Dodi Handy, President & CEO, Phone: (407) 585-1080, E-mail:chkt@efcg.net
